New Platform to Accelerate COVID-19 Tests into Real-World Use
By HospiMedica International staff writers Posted on 25 Jun 2020 |
Illustration
Testing for coronavirus infection could become quicker, more convenient and more accurate, following the launch of a multi-centre national program of research in the UK that will evaluate how new diagnostic tests perform in hospitals, general practices and care homes.
The COVID-19 National DiagnOstic Research and Evaluation Platform (CONDOR) will create a single national route for evaluating new diagnostic tests in hospitals and in community healthcare settings. The research program will bringing together experts who are highly experienced in evaluating diagnostic tests and generating the robust evidence required for a test to be used in the NHS.
Jointly led by the University of Oxford (Oxford, UK) and Manchester University NHS Foundation Trust (Manchester, UK), the program will put the many tests developed by the life sciences industry to either detect current coronavirus infection or to find out if someone has previously been infected through their paces in hospital, general practice, and care home environments. The research will assess multiple diagnostic tests at once at sites across the UK and can be adapted to add in new tests as they become available.
“Right now, there’s a critical gap in how we road-test new diagnostics for COVID-19. By robustly evaluating these diagnostics in health and care settings, the CONDOR program will help the government and clinicians to understand the real-world accuracy of these tests in patients presenting with COVID-19 symptoms in the NHS,” said co-primary investigator Professor Gail Hayward, Associate Professor at the University of Oxford’s Nuffield Department of Primary Care Health Sciences, and Deputy Director of the NIHR Community Healthcare MedTech and IVD Co-operative.
Related Links:
University of Oxford
Manchester University NHS Foundation Trust
The COVID-19 National DiagnOstic Research and Evaluation Platform (CONDOR) will create a single national route for evaluating new diagnostic tests in hospitals and in community healthcare settings. The research program will bringing together experts who are highly experienced in evaluating diagnostic tests and generating the robust evidence required for a test to be used in the NHS.
Jointly led by the University of Oxford (Oxford, UK) and Manchester University NHS Foundation Trust (Manchester, UK), the program will put the many tests developed by the life sciences industry to either detect current coronavirus infection or to find out if someone has previously been infected through their paces in hospital, general practice, and care home environments. The research will assess multiple diagnostic tests at once at sites across the UK and can be adapted to add in new tests as they become available.
“Right now, there’s a critical gap in how we road-test new diagnostics for COVID-19. By robustly evaluating these diagnostics in health and care settings, the CONDOR program will help the government and clinicians to understand the real-world accuracy of these tests in patients presenting with COVID-19 symptoms in the NHS,” said co-primary investigator Professor Gail Hayward, Associate Professor at the University of Oxford’s Nuffield Department of Primary Care Health Sciences, and Deputy Director of the NIHR Community Healthcare MedTech and IVD Co-operative.
Related Links:
University of Oxford
Manchester University NHS Foundation Trust
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans